Pancreatic Cancer Research

ResearcherAlbert Einstein College of MedicineActive in the last 2 years

Claudia Gravekamp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1713-3008; OpenAlex author ID A5010825732; NIH RePORTER profile ID 6421066. Sources: funder_awards.

Their work

Papers
6 (first author 0, last author 4)
Trials
1 (principal investigator on 1)
Grants
4
Labs led
1
Collaborators
11
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 grants · 2017: 1 paper, 1 trial · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 grant · 2025: none · 2026: 1 grant

Papers 6

  1. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Last author DOI 10.1126/scitranslmed.abc1600↗
  2. LY6 gene family presents a novel class of potential biomarkers associated with overall survival outcome of pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.27968↗
  3. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. Last author DOI 10.1136/jitc-2020-001250↗
  4. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Last author DOI 10.18632/oncotarget.15117↗
  5. Targeted radionuclide therapies for pancreatic cancer. Co-author DOI 10.1038/cgt.2015.32↗
  6. Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Last author DOI 10.1073/pnas.1211287110↗

Trials 1

  1. Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer Principal investigator NCT03848182↗

Grants 4

  1. Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients R42CA287679↗
  2. Monitoring Listeria in vivo using 18FDG and PET scan R21CA292190↗
  3. Improving Cancer Immunotherapy and Gemcitabine Sensitivity through Listeria AWARD pancan:2016-claudia-gravekamp-phd-improving-cancer-immunotherapy-and-gemci
  4. Treating pancreatic cancer with Listeria-32P R21CA199010↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Christopher McAuliffe · 1 shared paper, 1 shared grant, 2022–2026 · strength 0.97
  2. Chaoyuan Kuang · 1 shared grant, 2026 · strength 0.86
  3. Chris Bradley · 1 shared grant, 2026 · strength 0.86
  4. Benson Chellakkan Selvanesan · 3 shared papers, 2017–2022 · strength 0.30
  5. Dinesh Chandra · 3 shared papers, 2013–2022 · strength 0.21
  6. Ekaterina Dadachova · 3 shared papers, 2013–2017 · strength 0.17
  7. Wilber Quispe‐Tintaya · 2 shared papers, 2013–2022 · strength 0.15
  8. Ilse Rooman · 1 shared paper, 2020 · strength 0.13
  9. Vinod P. Balachandran · 1 shared paper, 2022 · strength 0.11
  10. Jennifer W. Chuy · 1 shared paper, 2022 · strength 0.11
  11. M Shah · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.